D.E. Shaw & Co
CARM

D.E. Shaw & Co’s Carisma Therapeutics CARM Stock Holding History

D.E. Shaw & Co’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,654
Closed -$137K – 5426
2021
Q3 		$137K Sell
8,654
-7,745
-47% -$372K ﹤0.01% 4657
2021
Q2 		$1.51M Buy
+16,399
New +$1.05M ﹤0.01% 3203
2019
Q3 		– Sell
-1,060
Closed -$32K – 3824
2019
Q2 		$32K Buy
+1,060
New +$31.7K ﹤0.01% 3605

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co's CARM Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Carisma Therapeutics (CARM) in Q4 2021, closing a stake of 8,654 shares — an estimated $137K sold.

D.E. Shaw & Co first reported a position in CARM in Q2 2019 and held it in 3 quarters. The position peaked at $1.51M in Q2 2021. 93 funds tracked by Wall St. Rank hold CARM as of Q4 2021.

  • D.E. Shaw & Co reported no remaining Carisma Therapeutics position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 8,654 Carisma Therapeutics shares in Q4 2021, an estimated $137K.
  • D.E. Shaw & Co first reported a position in Carisma Therapeutics in Q2 2019 and held it in 3 quarters.
  • D.E. Shaw & Co's Carisma Therapeutics position peaked at $1.51M in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.